CA2768658C - Methods for generating radioimmunoconjugates - Google Patents

Methods for generating radioimmunoconjugates Download PDF

Info

Publication number
CA2768658C
CA2768658C CA2768658A CA2768658A CA2768658C CA 2768658 C CA2768658 C CA 2768658C CA 2768658 A CA2768658 A CA 2768658A CA 2768658 A CA2768658 A CA 2768658A CA 2768658 C CA2768658 C CA 2768658C
Authority
CA
Canada
Prior art keywords
acid
reaction mixture
dota
antibody
hum195
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2768658A
Other languages
English (en)
French (fr)
Other versions
CA2768658A1 (en
Inventor
Jaime Simon
A. Gaylord King
Josue Manuel Moreno Bermudez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinium Pharmaceuticals Inc
Original Assignee
Actinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinium Pharmaceuticals Inc filed Critical Actinium Pharmaceuticals Inc
Publication of CA2768658A1 publication Critical patent/CA2768658A1/en
Application granted granted Critical
Publication of CA2768658C publication Critical patent/CA2768658C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2768658A 2009-07-22 2010-07-22 Methods for generating radioimmunoconjugates Active CA2768658C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22771009P 2009-07-22 2009-07-22
US61/227,710 2009-07-22
PCT/US2010/042885 WO2011011592A1 (en) 2009-07-22 2010-07-22 Methods for generating radioimmunoconjugates

Publications (2)

Publication Number Publication Date
CA2768658A1 CA2768658A1 (en) 2011-01-27
CA2768658C true CA2768658C (en) 2018-04-03

Family

ID=43499411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2768658A Active CA2768658C (en) 2009-07-22 2010-07-22 Methods for generating radioimmunoconjugates

Country Status (8)

Country Link
US (1) US9603954B2 (https=)
EP (1) EP2456472B1 (https=)
JP (2) JP5985392B2 (https=)
CN (2) CN104710504B (https=)
CA (1) CA2768658C (https=)
IN (1) IN2012DN00551A (https=)
RU (2) RU2704802C2 (https=)
WO (1) WO2011011592A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
US20150157742A1 (en) * 2013-12-11 2015-06-11 The European Atomic Energy Community (Euratom), Represented By The European Commission SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
US11660357B2 (en) * 2014-05-16 2023-05-30 David A. Scheinberg One-step labeling of antibodies to high specific activity with actinium-225
WO2017044530A1 (en) * 2015-09-08 2017-03-16 Waters Technologies Corporation Multidimensional chromatoggraphy method for analysis of antibody-drug conjugates
EP3554560A4 (en) * 2016-12-16 2020-07-29 The Australian National University RADIO-MARKED MATERIAL FOR TARGETED ADMINISTRATION
HRP20231458T1 (hr) 2017-01-12 2024-05-10 Radiomedix Inc. Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima
US20200121815A1 (en) * 2017-07-31 2020-04-23 Actinium Pharmaceuticals, Inc. Treatments for a hematological malignancy
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
US20230390424A1 (en) * 2020-09-11 2023-12-07 Actinium Pharmaceuticals, Inc. Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
US12447218B1 (en) * 2021-02-09 2025-10-21 Actinium Pharmaceuticals, Inc. Radioconjugates directed to MHC-complexed antigens in cancer
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
JP2025510189A (ja) * 2022-03-24 2025-04-14 アクティニウム ファーマシューティカルズ インコーポレイテッド ヒト化抗ｃｄ４５抗体
AU2023242087A1 (en) * 2022-03-30 2024-09-12 Nihon Medi-Physics Co., Ltd. Method for producing complex
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
US20250388688A1 (en) 2024-04-04 2025-12-25 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof
WO2026024644A1 (en) 2024-07-23 2026-01-29 Abdera Therapeutics Inc. 5t4 binding polypeptides and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001387A (en) 1973-07-30 1977-01-04 Medi-Physics, Inc. Process for preparing radiopharmaceuticals
US4305922A (en) 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4296785A (en) 1979-07-09 1981-10-27 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4732864A (en) 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4894364A (en) 1983-10-26 1990-01-16 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4663129A (en) 1985-01-30 1987-05-05 The United States Of America As Represented By The United States Department Of Energy Isotopic generator for bismuth-212 and lead-212 from radium
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5306509A (en) 1987-03-17 1994-04-26 Turner Robert E Prevention and treatment of oral lesions
AU2068588A (en) 1987-08-12 1989-02-16 Immunomedics Inc. Preparation of radiolabeled conjugates
US4833329A (en) 1987-11-20 1989-05-23 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
JPH0720989B2 (ja) 1988-05-25 1995-03-08 アメリカ合衆国 大環状キレート化合物の抱合体と診断的テスト方法
US5292868A (en) 1989-05-26 1994-03-08 Akzo N.V. Chelating agents for attaching metal ions to proteins
AU629367B2 (en) 1989-06-19 1992-10-01 Akzo N.V. Radioimmunotherapy using alpha-particles emission
AU645267B2 (en) 1989-07-12 1994-01-13 Mallinckrodt Medical, Inc. Preparation radiodiagnostic gaseous radionuclide
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
LU87684A1 (de) 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5038046A (en) 1990-07-10 1991-08-06 Biotechnetics Method and generator for producing radioactive lead-212
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (en) 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
ATE473242T1 (de) 1998-05-20 2010-07-15 Immunomedics Inc Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
JP5064608B2 (ja) * 1998-05-26 2012-10-31 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ アルファ粒子放出構成物およびその使用方法
US7074405B1 (en) 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6683162B2 (en) 2000-09-15 2004-01-27 Sloan Kettering Institute Of Cancer Research Targeted alpha particle therapy using actinium-255 conjugates
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
US20040136908A1 (en) * 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
US20030086868A1 (en) 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US20060058218A1 (en) * 2004-09-10 2006-03-16 General Electric Company Solid phase conjugation of complexing agents and targeting moieties
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
EP2015775B1 (en) * 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody

Also Published As

Publication number Publication date
EP2456472B1 (en) 2024-03-27
WO2011011592A1 (en) 2011-01-27
CN102596258B (zh) 2015-01-28
EP2456472A1 (en) 2012-05-30
JP5985392B2 (ja) 2016-09-06
RU2704802C2 (ru) 2019-10-31
HK1211304A1 (en) 2016-05-20
IN2012DN00551A (https=) 2015-06-12
EP2456472C0 (en) 2024-03-27
RU2565402C2 (ru) 2015-10-20
RU2015137512A (ru) 2018-12-25
JP2016199583A (ja) 2016-12-01
RU2012106301A (ru) 2013-08-27
JP2013500258A (ja) 2013-01-07
CA2768658A1 (en) 2011-01-27
US20120220754A1 (en) 2012-08-30
CN104710504A (zh) 2015-06-17
RU2015137512A3 (https=) 2019-04-02
US9603954B2 (en) 2017-03-28
CN102596258A (zh) 2012-07-18
CN104710504B (zh) 2019-09-13
EP2456472A4 (en) 2014-08-27

Similar Documents

Publication Publication Date Title
CA2768658C (en) Methods for generating radioimmunoconjugates
JP2025143317A (ja) ポリペプチドの放射性標識
Di Bartolo et al. New 64 Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr
Sarrett et al. Inverse electron demand Diels–Alder click chemistry for pretargeted PET imaging and radioimmunotherapy
CA2786655C (en) Novel radioimmunoconjugates that binds human cd37
AU687204B2 (en) Thiolation of proteins for radionuclide-based radioimmunodetection and radioimmunotherapy
CA2290987A1 (en) Radioprotectant for peptides labeled with radioisotope
KR20240035757A (ko) 우로키나제 플라스미노겐 활성화제 수용체-표적화된 방사성 약제
Coliva et al. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas
US20150157742A1 (en) SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
Yoo et al. N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein
HK1211304B (zh) 用於制备放射性免疫缀合物的方法
N’Guessan et al. Enhancing theranostic potential of anti-mesothelin sdAb through site-specific labeling at a unique conserved lysine by molecular engineering
Hinkle et al. Indium-111-monoclonal antibodies in radioimmunoscintigraphy
CA2836313A1 (en) Synthesis of biological compounds labeled with the alpha emitter ac-225
Bensimon et al. Antibody radiolabeling
HK1195736B (en) Radioimmunoconjugates and their use
HK1179157B (en) Radioimmunoconjugates and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150721

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240718

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240725

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707